Stockreport

Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID

Virios Therapeutics, Inc.  (VIRI) 
PDF - Placebo-Controlled Clinical Proof of Concept Data Expected in Mid-2024 -- Targeting Initiation of IMC-2 Phase 2 program in 2H 2024 - ATLANTA, Jan. 22, 2024 (GLOBE N [Read more]